INTRODUCTION: Small cell lung cancer (SCLC) is an aggressive malignancy with no established biomarkers. Schlafen 11(SLFN11), a DNA/RNA helicase that sensitises cancer cells to DNA-damaging agents, has emerged as a promising predictive biomarker for several drug classes including platinum and PARP inhibitors. Detection of SLFN11 in circulating tumour cells (CTCs) may provide a valuable alternative to tissue sampling. METHODS: SLFN11 expression was evaluated in tumour samples and characterised in circulating tumour cells (CTC) longitudinally to determine its potential role as a biomarker of response. RESULTS: Among 196 SCLC tumours, 51% expressed SLFN11 by IHC. In addition, 20/29 extra-thoracic high-grade neuroendocrine tumours expressed SLFN11 expression. In 64 blood samples from 42 SCLC patients, 83% (53/64) of samples had detectable CTCs, and SLFN11-positive CTCs were detected in 55% (29/53). Patients actively receiving platinum treatment had the lowest number of CTCs and a lower percentage of SLFN11-positive CTCs (p = 0.014). Analysis from patients with longitudinal samples suggest a decrease in CTC number and in SLFN11 expression that correlates with clinical response. CONCLUSIONS: SLFN11 levels can be monitored in CTCs from SCLC patients using non-invasive liquid biopsies. The ability to detect SLFN11 in CTCs from SCLC patients adds a valuable tool for the detection and longitudinal monitoring of this promising biomarker.
INTRODUCTION: Small cell lung cancer (SCLC) is an aggressive malignancy with no established biomarkers. Schlafen 11(SLFN11), a DNA/RNA helicase that sensitises cancer cells to DNA-damaging agents, has emerged as a promising predictive biomarker for several drug classes including platinum and PARP inhibitors. Detection of SLFN11 in circulating tumour cells (CTCs) may provide a valuable alternative to tissue sampling. METHODS: SLFN11 expression was evaluated in tumour samples and characterised in circulating tumour cells (CTC) longitudinally to determine its potential role as a biomarker of response. RESULTS: Among 196 SCLC tumours, 51% expressed SLFN11 by IHC. In addition, 20/29 extra-thoracic high-grade neuroendocrine tumours expressed SLFN11 expression. In 64 blood samples from 42 SCLC patients, 83% (53/64) of samples had detectable CTCs, and SLFN11-positive CTCs were detected in 55% (29/53). Patients actively receiving platinum treatment had the lowest number of CTCs and a lower percentage of SLFN11-positive CTCs (p = 0.014). Analysis from patients with longitudinal samples suggest a decrease in CTC number and in SLFN11 expression that correlates with clinical response. CONCLUSIONS: SLFN11 levels can be monitored in CTCs from SCLC patients using non-invasive liquid biopsies. The ability to detect SLFN11 in CTCs from SCLC patients adds a valuable tool for the detection and longitudinal monitoring of this promising biomarker.
Authors: William D Travis; Elisabeth Brambilla; Allen P Burke; Alexander Marx; Andrew G Nicholson Journal: J Thorac Oncol Date: 2015-09 Impact factor: 15.609
Authors: Vincenza Conteduca; Sheng-Yu Ku; Loredana Puca; Megan Slade; Luisa Fernandez; Judy Hess; Rohan Bareja; Panagiotis J Vlachostergios; Michael Sigouros; Juan Miguel Mosquera; Andrea Sboner; David M Nanus; Olivier Elemento; Ryan Dittamore; Scott T Tagawa; Himisha Beltran Journal: Mol Cancer Ther Date: 2020-03-03 Impact factor: 6.261
Authors: Kathryn L Simpson; Ruth Stoney; Kristopher K Frese; Nicole Simms; William Rowe; Simon P Pearce; Sam Humphrey; Laura Booth; Derrick Morgan; Marek Dynowski; Francesca Trapani; Alessia Catozzi; Mitchell Revill; Thomas Helps; Melanie Galvin; Luc Girard; Daisuke Nonaka; Louise Carter; Matthew G Krebs; Natalie Cook; Mathew Carter; Lynsey Priest; Alastair Kerr; Adi F Gazdar; Fiona Blackhall; Caroline Dive Journal: Nat Cancer Date: 2020-04-13
Authors: C Allison Stewart; Carl M Gay; Yuanxin Xi; Santhosh Sivajothi; V Sivakamasundari; Junya Fujimoto; Mohan Bolisetty; Patrice M Hartsfield; Veerakumar Balasubramaniyan; Milind D Chalishazar; Cesar Moran; Neda Kalhor; John Stewart; Hai Tran; Stephen G Swisher; Jack A Roth; Jianjun Zhang; John de Groot; Bonnie Glisson; Trudy G Oliver; John V Heymach; Ignacio Wistuba; Paul Robson; Jing Wang; Lauren Averett Byers Journal: Nat Cancer Date: 2020-02-17
Authors: Andrew J Armstrong; Susan Halabi; Jun Luo; David M Nanus; Paraskevi Giannakakou; Russell Z Szmulewitz; Daniel C Danila; Patrick Healy; Monika Anand; Colin J Rothwell; Julia Rasmussen; Blair Thornburg; William R Berry; Rhonda S Wilder; Changxue Lu; Yan Chen; John L Silberstein; Gabor Kemeny; Giuseppe Galletti; Jason A Somarelli; Santosh Gupta; Simon G Gregory; Howard I Scher; Ryan Dittamore; Scott T Tagawa; Emmanuel S Antonarakis; Daniel J George Journal: J Clin Oncol Date: 2019-03-13 Impact factor: 44.544
Authors: Claudia Winkler; Joshua Armenia; Gemma N Jones; Luis Tobalina; Matthew J Sale; Tudor Petreus; Tarrion Baird; Violeta Serra; Anderson T Wang; Alan Lau; Mathew J Garnett; Patricia Jaaks; Elizabeth A Coker; Andrew J Pierce; Mark J O'Connor; Elisabetta Leo Journal: Br J Cancer Date: 2020-12-18 Impact factor: 7.640
Authors: M Catherine Pietanza; Saiama N Waqar; Lee M Krug; Afshin Dowlati; Christine L Hann; Alberto Chiappori; Taofeek K Owonikoko; Kaitlin M Woo; Robert J Cardnell; Junya Fujimoto; Lihong Long; Lixia Diao; Jing Wang; Yevgeniva Bensman; Brenda Hurtado; Patricia de Groot; Erik P Sulman; Ignacio I Wistuba; Alice Chen; Martin Fleisher; John V Heymach; Mark G Kris; Charles M Rudin; Lauren Averett Byers Journal: J Clin Oncol Date: 2018-06-15 Impact factor: 44.544